Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Spit test could spot ovarian cancer earlier

NCT ID NCT05514028

Diagnosis Sponsor: ZIWIG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether RNA in saliva can help tell the difference between ovarian cancer, borderline tumors, and benign cysts. Researchers are collecting saliva samples from 746 women before and after surgery. The goal is to find a simple, non-invasive way to speed up diagnosis and improve care for women with ovarian masses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple saliva test to quickly identify ovarian cancer, reducing diagnosis time and improving treatment pathways.
What could go wrong
This is an observational study, not a treatment trial. The test may not prove accurate enough for clinical use, and results are still early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

746 people

The number who actually took part.

Started

May 2022

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of patients with an ovarian adnexal mass diagnosed by clinical examination and imaging (pelvic ultrasound and/or MRI and/or blood tumour markers) and requiring surgical management in routine care. The patients concerned by the study already benefit from a surgical management in different gynecology-obstetrics/gynecological oncology departments in France, Canada and Tunisia, as well as from a validation of the therapeutic indications in accordance with the national practices in force. The patients concerned by the study will be managed without modification of the care pathway, nor modification of the therapeutic indications, nor modification of the diagnostic or follow-up examinations (imaging and/or blood tumour markers) necessary according to the context which are carried out according to the national and/or international recommendations in force.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient over 18 years of age, * A patient with an ovarian adnexal mass diagnosed by clinical examination and imaging and likely to be ovarian cancer, a borderline tumour or a benign cyst, * Patient with an indication for surgery * Patient has dated and signed the consent form, * Patient affiliated to the healthcare system, Exclusion Criteria: * Pregnant patient * Patient infected with human immunodeficiency virus (HIV), * Patient with significant difficulties in reading or writing the French language. * Patient with another diagnosed cancer * Patient with a history of cancer less than 5 years old

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Borderline ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

borderline epithelial tumor of ovary neoplasm ovarian cancer ovarian cyst

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Borderline ovarian cancer Ovarian cancer Ovarian cyst benign

Contacts and locations

Locations

  • CGFL

    Dijon, Côte d'Or, 21079, France

  • CH Bastia

    Bastia, 20600, France

  • CH Niort

    Niort, 79021, France

  • CHP St Grégoire

    Saint-Grégoire, Ille Et Villaine, 35760, France

  • CHRU Bretonneau-Tours

    Tours, 37044, France

  • CHU Angers

    Angers, 49933, France

  • CHU Lyon Sud / Hospices Civils de Lyon

    Lyon, 69000, France

  • CHU Rennes

    Rennes, 35000, France

  • CHU Rouen, Hôpital de Bois-Guillaume

    Rouen, France

  • CHU Strasbourg

    Strasbourg, Haut-Rhin, 67200, France

  • CHU Tenon

    Paris, 75020, France

  • CHU Toulouse

    Toulouse, Haute-Garonne, 31059, France

  • CHU de Caen

    Caen, Calvados, 14000, France

  • Centre Antoine Lacassagne

    Nice, France

  • Centre de Maternité et de Néonatologie Wassila Bourguiba

    Tunis, 01007, Tunisia

  • Clinique La sagesse

    Rennes, France

  • Clinique Pasteur

    Toulouse, France

  • Hôpital BICETRE

    Le Kremlin-Bicêtre, Val de Marne, 94275, France

  • Institut Bergonié

    Bordeaux, Gironde, 33076, France

  • Institut Gustave Roussy

    Villejuif, Val de Marne, 94805, France

  • Universitätsklinik für Frauenheilkunde

    Bern, 03010, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.